Cell and Gene Outsourcing

31. May 2025 — CDMO Opportunities And Threats Report 6/4/2025

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

32. The Matryoshka Model: The New Face Of Contract Packaging In Pharma 6/4/2025

    Contract packaging organizations are the outer layer of the pharmaceutical Matryoshka (the iconic Russian nesting doll): the final form that contains within it a series of intricately crafted parts.

33. Building A Burgeoning Advanced Therapy Infrastructure In The Middle East 6/2/2025

    In this conversation, Dr. Boro Dropulić, Executive Director of Caring Cross, shares his perspective on regional challenges, opportunities for innovation, and the role of global partnerships.

34. The Advantages Of Off-The-Shelf GMP iPSCs With A DMF 6/2/2025

    Learn how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.

35. ActiCells™ RUO Hypo hiPSCs 6/2/2025

    Accelerate your allogeneic development by starting with a hypoimmunogenic iPSC platform reprogrammed from CD34+ cord blood cells.

36. ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-In Kit 6/2/2025

    Rapidly advance your allogeneic development with a hypoimmunogenic iPSC platform that has pre-built TARGATT™ large knock-in technology.
37. iPSC Gene Editing Services 6/2/2025

    From precise edits to robust expression, get iPSC genome editing done right — from the experienced innovators in gene editing and iPSC technology.

38. Establishing A Versatile Platform For Intensified Lentiviral Vector Manufacturing 6/2/2025

    Accelerate access to high-quality, cost-effective lentiviral vectors with our intensified TFDF-based manufacturing platform, delivering multi-fold yield improvements and scalable, space-efficient production.

39. Optimizing AAV8 Capsid Purification With Oversized GOI 6/2/2025

    Enhance AAV gene therapy quality and regulatory compliance with our advanced AEX-based purification platform, achieving >90% full capsid purity — even for oversized AAV8 vectors.

40. Optimization Of rAAV Production Using An In-House Suspension HEK293 Cell Line 6/2/2025

    Boost rAAV yields and quality while reducing costs with our proprietary HEK293 cell line and scalable, optimized manufacturing platform for gene therapy.